S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Total Receivables
ÂĄ31.3m
CAGR 3-Years
69%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
ÂĄ3.2B
CAGR 3-Years
77%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Receivables
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Receivables
ÂĄ3.1B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Receivables
ÂĄ25.5B
CAGR 3-Years
34%
CAGR 5-Years
41%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Total Receivables
ÂĄ230.8m
CAGR 3-Years
72%
CAGR 5-Years
75%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
31.3m CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Total Receivables amounts to 31.3m CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 3Y
69%

Over the last year, the Total Receivables growth was 9%. The average annual Total Receivables growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been 69% over the past three years .

Back to Top